Build an osteoporosis treatment initiation: FRAX thresholds, DEXA follow-ups, therapy…
- User
Build an osteoporosis treatment initiation: FRAX thresholds, DEXA follow-ups, therapy choices, and adherence.
- Assistant
Osteoporosis Treatment Initiation Protocol
This protocol is based on major guidelines (NOF 2021 Clinician's Guide, Endocrine Society 2020, AACE 2020). It applies primarily to postmenopausal women and men ≥50 years. Individualize based on patient factors (e.g., CKD, GI history, fracture history). Always confirm with latest evidence and consult endocrinology/rheumatology as needed.
1. Patient Assessment & FRAX Thresholds for Treatment Initiation
-
Prerequisites:
- History: Prior fragility fracture (hip/spine/wrist), parental hip fracture, current smoking, ≥3 drinks/day alcohol, glucocorticoid use ≥3 months, secondary causes (e.g., hyperthyroidism, malabsorption).
- Labs: 25-OH vitamin D (target ≥30 ng/mL; replete if low), calcium, Cr/eGFR, PTH, TSH if indicated. Rule out secondary osteoporosis.
- BMD: DEXA (spine, hip, forearm). T-score ≤ -2.5 at any site = osteoporosis → treat regardless of FRAX.
-
FRAX Calculation (10-year risk tool: shef.ac.uk/FRAX):
Risk Category Hip Fracture Risk Major Osteoporotic Fracture (MOF) Risk Action Low <3% <20% Lifestyle + monitor (repeat FRAX/DEXA in 3-5 yrs). Moderate 3-7.5% 20-30% or T-score -1.5 to -2.5 Consider treatment if high clinical risk (e.g., recent fracture). High ≥3% ≥20% or T-score ≤ -2.5 Initiate pharmacologic therapy. -
Initiate Treatment If:
- Hip FRAX ≥3% OR MOF FRAX ≥20% OR T-score ≤ -2.5 OR recent fragility fracture OR FRAX ≥ threshold + high clinical risk.
2. DEXA Follow-Up Schedule
-
Baseline: DEXA prior to therapy initiation (unless recent <12 months).
-
Monitoring (assess response: ≥3-5% BMD increase at spine/hip or stable):
Therapy Type Follow-Up Interval Notes Bisphosphonates 2 years, then every 2-3 yrs Stop after 3-5 yrs (drug holiday if low risk). Denosumab 1-2 years Never abrupt stop (risk of rebound fractures); transition to bisphosphonate. Anabolics (teriparatide/romosozumab) 1 year (end of course) Follow with antiresorptive. Max 2 yrs lifetime for teriparatide. All Annually if high risk (e.g., ongoing fractures, glucocorticoid use) VFA (vertebral fracture assessment) at baseline/follow-up. -
Non-Response (BMD loss >4% spine or >0.5% hip at 2 yrs): Switch therapy, investigate adherence/secondary causes.
3. Therapy Choices
All patients: Lifestyle foundation – Weight-bearing exercise (30 min/day), fall prevention, calcium 1200 mg/day, vitamin D 2000 IU/day, smoking cessation, limit alcohol.
Risk Level Preferred First-Line Alternatives Duration Key Considerations Very High (recent hip/vertebral fx, ≥2 fx, FRAX hip ≥7.5%, T-score ≤-3.5, FRAX + glucocorticoid) Anabolic: Romosozumab (210 mg SQ monthly x12 mo) → transition to bisphosphonate/denosumab.OR Teriparatide (20 mcg SQ daily x≤24 mo). Denosumab if anabolic contraindicated. Anabolic: 12-24 mo, then antiresorptive. CV risk (romosozumab); hypercalcemia (teriparatide). High (FRAX thresholds met, no "very high" features) Antiresorptive:- Oral bisphosphonate: Alendronate 70 mg weekly (1st-line).- IV: Zoledronate 5 mg yearly (preferred if poor adherence/GI issues). Denosumab 60 mg SQ q6 mo (renal impairment). Raloxifene 60 mg daily (if high VTE risk low). 3-5 yrs, then reassess for holiday. Esophagitis (oral); ONJ/ATF rare (<0.1%). Moderate (borderline FRAX, T-score -2.0 to -2.5) Oral bisphosphonate. HRT (limited use, <60 yrs). 3 yrs, reassess. Monitor adherence closely. - Special Populations:
Population Therapy Notes eGFR <30-35 Denosumab or teriparatide (avoid zoledronate/alendronate). Glucocorticoid-induced Teriparatide 1st-line if high dose/long-term. Men Same as women; consider testosterone if low. Asian/Short stature Lower FRAX thresholds (adjust for ethnicity).
4. Adherence Strategies (Target >80%; real-world ~50% at 1 yr)
- Baseline Counseling (30-45 min): Explain fracture risk reduction (30-70%), visuals (FRAX output), side effects (5-10% GI for oral).
- Tools:
Strategy Implementation Simplified Regimen Weekly oral or q6-12 mo IV/SQ → >70% adherence. Reminders App/text (e.g., Medisafe), blister packs, family involvement. Monitoring Prescription refill rates, urine markers (if available), DEXA response. Barriers Address GI prophylaxis (take upright w/water, avoid NSAIDs); cost assistance (patient programs). - Follow-Up: q3-6 mo phone/virtual x1 yr, then annually. Reassess adherence/BMD/fractures.
- Non-Adherent: Switch to long-interval therapy; behavioral interventions.
Treatment Algorithm Summary
Assess Risk (History + Labs + DEXA + FRAX) ↓ High/Very High Risk? → Start Therapy + Lifestyle ↓ Choose Agent (per table) + Baseline DEXA ↓ Follow-Up: Adherence check q3 mo, DEXA per schedule ↓ Response? → Continue/Reassess Holiday No → Switch/InvestigatePearl: 50% fractures occur with T-score > -2.5 – FRAX integrates clinical risk. Document shared decision-making. Update with new trials (e.g., romosozumab data).
-
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.